famotidine has been researched along with Cancer of Ovary in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paclitaxel Css values were not significantly different in individual patients when either cimetidine or famotidine preceded paclitaxel (p = 0." | 2.68 | Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. ( Bowling, MK; Chen, TL; Donehower, RC; McGuire, WP; Rowinsky, EK; Slichenmyer, WJ, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Slichenmyer, WJ | 1 |
| Donehower, RC | 1 |
| Chen, TL | 1 |
| Bowling, MK | 1 |
| McGuire, WP | 1 |
| Rowinsky, EK | 1 |
1 trial available for famotidine and Cancer of Ovary
| Article | Year |
|---|---|
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Topics: Adult; Aged; Cimetidine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Famotidine; Female; His | 1995 |